Does race predict survival for women with invasive breast cancer?
- PMID: 31206623
- PMCID: PMC6752887
- DOI: 10.1002/cncr.32296
Does race predict survival for women with invasive breast cancer?
Abstract
Background: Black women with breast cancer have lower survival rates and higher recurrence rates in comparison with white women. This study compared treatment and survival outcomes for black and white women at a highly specialized tertiary care cancer center.
Methods: An institutional review board-approved, retrospective institutional database review was performed to identify all black women treated for invasive breast cancer between 2005 and 2010. Women with a prior history of breast cancer, stage IV cancer, or bilateral breast cancer were excluded. White women had similar exclusion criteria applied and were then matched to black women 1:1 by age and diagnosis year. Clinicopathologic and treatment variables were compared by race. Kaplan-Meier methodology was used to estimate overall survival (OS) and disease-free survival (DFS); a multivariable analysis was conducted with Cox regression models.
Results: The study group consisted of 1332 women (666 black). The median tumor size was larger in black women (1.6 vs 1.3 cm; P < .001). Black women had more nodal disease (41.1% vs 32%; P < .001) and had tumors that were more frequently an estrogen receptor-negative (32.9% vs 15%; P < .001), progesterone receptor-negative (47.1% vs 30.2%; P < .001), or triple-negative (TN) subtype (24% vs 8.9%; P < .001) in comparison with white women. Black women also had inferior DFS and OS; race was not an independent prognostic indicator in the multivariable analysis.
Conclusions: Black women had more advanced disease and adverse prognostic indicators at diagnosis, but race was not an independent predictor of outcome. Black women were significantly more likely to have TN breast cancer. Further research is necessary to understand the differences in tumor biology associated with race.
Keywords: African American; black women; breast cancer; disparities; race; survival; triple-negative breast cancer.
© 2019 American Cancer Society.
Conflict of interest statement
CONFLICT OF INTEREST DISCLOSURES
Dr. Monica Morrow has received speaking honoraria from Roche and Genomic Health.
Figures
Comment in
-
Race, breast cancer, and prognosis: Where biology is queen?Cancer. 2019 Sep 15;125(18):3104-3106. doi: 10.1002/cncr.32294. Epub 2019 Jun 17. Cancer. 2019. PMID: 31206611 No abstract available.
References
-
- DeSantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI, et al. Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. CA Cancer J Clin. 2016;66(4):290–308. - PubMed
-
- Richardson LC, Henley SJ, Miller JW, Massetti G, Thomas CC. Patterns and Trends in Age-Specific Black-White Differences in Breast Cancer Incidence and Mortality - United States, 1999-2014. MMWR Morb Mortal Wkly Rep. 2016;65(40):1093–8. - PubMed
-
- Howard-McNatt M, Lawrence J, Melin SA, Levine EA, Shen P, Stewart JHt. Race and recurrence in women who undergo neoadjuvant chemotherapy for breast cancer. Am J Surg. 2013;205(4):397–401. - PubMed
-
- Tannenbaum SL, Koru-Sengul T, Miao F, Byrne MM. Disparities in survival after female breast cancer diagnosis: a population-based study. Cancer Causes Control. 2013;24(9):1705–15. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
